Your JM Support Community

Cure JM helps patients and their families navigate life with juvenile myositis.

Two happy children: one with "Hope" chalkboard sign and the other holding a red balloon.

Cure JM is the global leader in juvenile myositis (JM) research. We are paving the way to better treatments for JM while improving the lives of families affected by the disease.

About
Juvenile Myositis

Juvenile myositis involves a run-away immune response where the body’s immune system attacks its own cells and tissues. With proper treatment and care, children can go on to live their best lives.

Was your child recently diagnosed with juvenile myositis?

Resources

Cure JM is a family of families. We have many resources to help the whole family with the JM journey.

Get Involved

Discover the many ways you can support and connect with Cure JM.

A family participates in a Cure JM event.
Play Video

Finding a Cure and Better Treatments for Juvenile Myositis

Cure JM is accelerating juvenile myositis research at an unprecedented pace. We are pursuing promising new treatments, funding clinical trials, and improving care for patients.

Accelerate
Research
Pursue Promising
New Treatments
Fund Clinical
Trials
Expand Our Clinical
Care Network

Current Events

The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify new biomarkers in JM and improve precise, personalized care through the identification of cell-to-cell interactions that drive inflammation in juvenile myositis.

Read More

The Cure JM Family Conference is back! Join families from around the country to learn about the latest treatment and research advances to share in our hope and progress.

Save the Date: Thursday, June 29–Sunday, July 2, 2023

Read More

ProDerm Study Reports a Milestone in Managing Adult Myositis

Recently, the Progress in Dermatomyositis ProDERM study published in the New England Journal of Medicine reported a milestone in managing adult myositis. With the trial’s favorable results, adult myositis patients have new hope with the approval of Octagam® 10%.

Read More

A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients.

Read More

Photo of a young couple

“Cure JM has provided us so much support and connected us to so many families that were experiencing or had experienced the exact same thing. That sense of community helped us get through the ups and downs.”

Leah, Olivia's Mom

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.